This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.

NAION is often referred to as an ‘eye stroke’, it causes sudden, painless vision loss - usually in one eye, but sometimes in both eyes.

Compounding pharmacies are illegally selling GLP-1 drugs, and the FDA is determined to shut that pathway down.

NAION is often referred to as an ‘eye stroke’, it causes sudden, painless vision loss - usually in one eye, but sometimes in ...

The UK is one of the heaviest nations in Europe now with 64 per cent of the population overweight or obese, and one in four ...

Researchers analyzed nearly 8,000 patients stopping semaglutide or tirzepatide. Most patients maintained weight or continued losing weight after one year, often by restarting therapy, switching ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...

“The bottom line I would convey to patients is that tried and true lifestyle interventions — adequate protein, fiber, ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved ...

Performance-enhancing peptides are increasingly popular among fitness enthusiasts and biohackers, despite limited human ...